Imago BioSciences Inc (NASDAQ:IMGO)’s stock price fell 10.2% on Friday . The stock traded as low as $17.91 and last traded at $17.91. 4,709 shares changed hands during trading, a decline of 98% from the average session volume of 233,432 shares. The stock had previously closed at $19.95.
IMGO has been the subject of several analyst reports. Jefferies Financial Group restated a “buy” rating and set a $37.00 target price on shares of Imago BioSciences in a research report on Monday, December 13th. Zacks Investment Research lowered Imago BioSciences from a “hold” rating to a “sell” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $34.33.
The company’s 50 day simple moving average is $21.98.
Large investors have recently made changes to their positions in the stock. Emerald Mutual Fund Advisers Trust acquired a new position in Imago BioSciences in the third quarter valued at $10,709,000. Morgan Stanley purchased a new stake in Imago BioSciences during the third quarter worth about $50,000. Geode Capital Management LLC purchased a new stake in Imago BioSciences during the third quarter worth about $2,900,000. Citigroup Inc. purchased a new stake in Imago BioSciences during the third quarter worth about $30,000. Finally, Perceptive Advisors LLC acquired a new position in Imago BioSciences during the third quarter worth about $2,504,000. Hedge funds and other institutional investors own 71.11% of the company’s stock.
About Imago BioSciences (NASDAQ:IMGO)
Imago BioSciences Inc is a clinical stage biopharmaceutical company. It involved in discovering new medicines for the treatment of myeloproliferative neoplasms. Imago BioSciences Inc is based in SOUTH SAN FRANCISCO, Calif.
Read More: Cost Basis
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.